CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
在复发/难治性 B 细胞急性淋巴细胞白血病成人患者中对抗原靶向抗体与细胞疗法的序贯治疗
英文原题：Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
查看英文原题
Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
近期四种靶向CD19或CD22的疗法获批用于B细胞急性淋巴细胞白血病（B-ALL），改变了复发/难治性（r/r）疾病的治疗格局。患有r/r B-ALL的成人通常符合所有选项的资格，但尚无研究直接比较这些药物，治疗医师必须决定选择哪一种。每种疗法作为单药均具有显著活性，但在特定情况下存在局限性，最佳选择因人而异。这些疗法可以互补，并可序贯或同时使用。在此，我们综述了r/r B-ALL抗原靶向疗法的当前格局，并讨论了其使用的考量因素。
展开英文摘要原文
The recent approvals of four CD19-or CD22-targeted therapies for B-cell acute lymphoblastic leukemia (B-ALL) have transformed the treatment of relapsed/refractory (r/r) disease. Adults with r/r B-ALL are usually eligible for all options, but there are no studies directly comparing these agents, and the treating physician must decide which to select.
Each therapy has notable activity as a single agent but has limitations in particular settings, and the optimal choice varies. These therapies can be complementary and used either sequentially or concomitantly.
Here, we review the current landscape of antigen-targeted therapies for r/r B-ALL and discuss considerations for their use.
论文信息
- 作者
- Aldoss I、Shah BD、Park JH、Muffly L、Logan AC、Brown P、Stock W、Jabbour EJ
- 第一作者单位
- Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.United States
- 通讯作者单位
- Division of Cancer Medicine, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.United States
- 文献类型
- 综述
- 期刊
- American journal of hematology2023 Apr
- 原文标识
- PubMed 36691748 · DOI 10.1002/ajh.26853